aTyr Pharma to Present at Upcoming Investor Conferences in March
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, a biotherapeutics company focused on innovative medicines, will have its President and CEO, Sanjay S. Shukla, present at two investor conferences in March 2022. The first is the 34th Annual ROTH Conference from March 13-15, featuring a pre-recorded presentation. The second, the Oppenheimer 32nd Annual Healthcare Conference, is on March 16 at 4:40 PM EDT. One-on-one investor meetings will also be held. Replays of the presentations will be available on their website.
- None.
- None.
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences in March.
Details of the events are as follows:
Conference: 34th Annual ROTH Conference
Date: March 13 – 15, 2022
Time: Pre-recorded Corporate Presentation available on demand
Conference: Oppenheimer 32nd Annual Healthcare Conference
Date: Wednesday, March 16, 2022
Time: Live virtual Corporate Presentation at 4:40pm EDT / 1:40pm PDT
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. Following the events, a replay of each presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com
FAQ
What is aTyr Pharma's stock symbol?
When will aTyr Pharma present at the ROTH Conference?
What time is the Oppenheimer Conference presentation for aTyr Pharma?
Will aTyr Pharma hold one-on-one meetings with investors?
Where can I find replays of aTyr Pharma's presentations?
